Corona Remedies IPO: Complete Guide to Date, Price, Allotment & Investment Review 2025
Corona Remedies Limited is set to make its stock market debut on December 15, 2025, marking a significant milestone for one of India's fastest-growing pharmaceutical companies. This comprehensive guide covers everything you need to know about the Corona Remedies IPO, including the opening date, price band, allotment details, and whether this pharmaceutical IPO is worth your investment.
Corona Remedies IPO: Key Dates & Timeline
Understanding the IPO timeline is crucial for investors planning to apply. Here's the complete Corona Remedies IPO schedule:
Retail investors have a 3-day window (December 8-10) to place their bids through ASBA (Authorized Subscription and Bidding for Allotment) online or offline through their brokers.
Corona Remedies IPO Price Band & Issue Size
The Corona Remedies IPO has been priced aggressively to capture investor sentiment in the pharmaceutical sector:
- IPO Price Band: ₹1,008 to ₹1,062 per equity share
- Face Value: ₹10 per share
- Total Issue Size: ₹655.37 crores
- Issue Type: Entirely Offer for Sale (OFS)
- Lot Size: 14 shares (minimum bid quantity)
- Minimum Investment (Retail): ₹14,868 (at upper price band)
- Maximum Investment (Retail): ₹1,93,284 (13 lots)
The IPO is a book-built issue, meaning the final price will be determined within the specified band based on investor demand and subscription response during the bidding period.
Corona Remedies IPO Lot Size & Investor Categories
The Corona Remedies IPO caters to different investor categories with varying lot requirements:
Retail Investors
- Minimum Lot: 1 lot (14 shares)
- Maximum Lot: 13 lots (182 shares)
- Allocation: 35% of total issue
- Investment Range: ₹14,868 to ₹1,93,284
Small High Net Worth Individuals (S-HNI)
- Minimum: 14 lots (196 shares) - ₹2,08,152
- Maximum: 67 lots (938 shares) - ₹9,96,156
- Allocation: 15% of total issue
Big High Net Worth Individuals (B-HNI)
- Minimum: 68 lots (952 shares) - ₹10,11,024
- Maximum: Unrestricted
- Allocation: Part of the 15% HNI quota
Qualified Institutional Buyers (QIB)
- Allocation: 50% of total issue
- Reserved exclusively for institutional investors
Corona Remedies IPO Allotment & Refund Process
The allotment process follows a standardized timeline:
- Allotment Date: December 11, 2025
- Investors can check allotment status on NSE and BSE websites
- Use PAN or application number to verify allotment
- Refunds & Credit: December 12, 2025
- Refunds will be initiated for unsuccessful bids
- Shares credited to Demat accounts same day
- Refund amount automatically credited to bank account
- Listing: December 15, 2025
- Shares will trade on BSE and NSE
- Market will determine actual stock price
Corona Remedies Company Profile & Business Overview
Corona Remedies Limited is a pharmaceutical powerhouse with strong fundamentals and a proven track record:
Company Background:
- Founded: August 2004
- Headquarters: Ahmedabad, Gujarat
- Industry: Branded Pharmaceutical Formulations
- Market Position: 2nd fastest-growing among top 30 Indian pharma companies (MAT June 2022 - June 2025)
Business Operations:Corona Remedies manufactures and markets pharmaceutical formulations across multiple therapeutic areas:
- Women's Healthcare: 28.56% of sales - Gynecological products, fertility treatments
- Cardio-Diabeto: 23.38% of sales - Cardiovascular and anti-diabetic medications
- Pain Management: 11.79% of sales - Analgesics and anti-inflammatory drugs
- Urology: 4.53% of sales - Urological treatments
- Other Therapeutics: Including vitamins, gastroenterology, respiratory care
Product Portfolio:
- 71 brands across diverse therapeutic areas
- 67 distinct therapeutic formulations marketed nationally
- Strong presence in chronic disease segments
- Pan-India distribution network with 2,671 medical representatives across 22 states
- 2 manufacturing facilities located in Gujarat with 1,285.44 million units per annum capacity
Corona Remedies IPO Financials & Performance Metrics
Understanding the company's financial health is essential for IPO investment decisions:
Revenue & Profitability Growth
Growth Rates:
- Revenue CAGR (FY23-25): 16.77% (vs. IPM CAGR of 9.21%)
- PAT Growth (FY24-25): 65% increase
- Revenue Growth (FY24-25): 18% increase
- Domestic Sales CAGR (MAT June 2022-25): 16.77%
Key Performance Indicators (KPIs)
Financial Health Assessment:Corona Remedies demonstrates exceptional financial strength with:
- Strong profitability margins exceeding 20% EBITDA
- Minimal debt with D/E ratio of just 0.10
- Consistent growth in revenue and profits
- Healthy liquidity with positive cash flows
Corona Remedies IPO Valuation & P/E Ratio Analysis
IPO Valuation Metrics
Peer Comparison Analysis
Valuation Analysis:Corona Remedies' P/E ratio of 43.47x is moderate compared to large-cap peers like Abbott India (54.28x) and Mankind Pharma (54.17x), but higher than smaller-cap peers like Alkem Labs (32.96x). The valuation reflects:
- Strong growth trajectory (16.77% revenue CAGR)
- Excellent returns (ROCE 41.32%, ROE 27.50%)
- Market leadership in high-growth segments
Corona Remedies IPO Merchant Bankers & Registrar
Book-Running Lead Managers (BRLMs):
- JM Financial Ltd.
- IIFL Capital Services Ltd.
- Kotak Mahindra Capital Co. Ltd.
IPO Registrar:
- Bigshare Services Pvt. Ltd.
- Phone: +91-22-6263 8200
- Email:
- ipo@bigshareonline.com
- Website: https://ipo.bigshareonline.com/IPO_Status.html
How to Apply for Corona Remedies IPO: Step-by-Step Guide
Investing in Corona Remedies IPO is straightforward through IPO Ji or your bank/broker:
Prerequisites for IPO Application
Before applying for the Corona Remedies IPO online, ensure you have the following in place:
- Valid PAN Card - Issued by the Income Tax Department
- Active Demat Account - For holding shares in electronic format (mandatory for all equity investments)
- Trading Account - While not mandatory for IPO application, it simplifies the process
- Active Bank Account - Linked to your demat account for fund management
- Sufficient Funds - Ensure your linked bank account has adequate balance for your IPO bid
Corona Remedies IPO Application Process for Retail Investors
Method 1: Applying for IPOs is now seamless with the IPO Ji App. Follow these steps:
- Download & Register on IPO Ji App.
- Go to the Corona Remedies IPO Page.
- Enter UPI ID, Lot Size, and Price.
- Confirm UPI mandate on your banking app.
- Track allotment status and listing updates directly on IPO Ji.
Method 2: Online Application via Broker/Trading Platform
- Log in to your broker's platform - Access your trading account on platforms like Zerodha, Angel One, 5paisa, Kotak Securities, or HDFC Securities
- Navigate to IPO section - Click on the IPO tab or investment section
- Select Corona Remedies IPO - Choose from the available IPO list
- Enter bid details - Specify the number of lots (minimum 1 lot = 76 shares) and your bidding price within the price band (₹185-₹195)
- Confirm UPI mandate - Approve the UPI payment mandate to automatically block your bid amount
- Submit application - Finalize and submit your IPO bid
- Save confirmation number - Keep your unique transaction reference for tracking
Method 3: ASBA Application via Bank
- Log into net banking - Access your bank's online banking portal
- Select IPO Application - Choose the demat/investment services section
- Fill ASBA form - Provide required details including bank account, PAN, demat account number
- Enter bid quantity and price - Bid for your desired number of shares within the price band
- Submit application - Confirm and submit the ASBA application
- Funds blocking - Your bid amount remains blocked in your account until allotment
Corona Remedies IPO: Detailed Industry Analysis
Indian Pharmaceutical Market Overview
Market Size & Growth:
- FY 2024 Market Size: ₹61.36 Billion USD
- FY 2025 Projected Size: US $13.48 Billion (domestic)
- Domestic Market: ₹4,71,295 crores (₹55 billion USD)
- 2030 Projection: ₹10,28,280 - 11,13,970 crores (₹120-130 billion USD)
- Projected CAGR (2025-2030): 5.31% to 11.32%
Market Composition:
- Domestic consumption: ₹2,01,372 crores (FY24)
- Industry turnover: ₹2,25,000 crores (FY25)
- Leading Segments: Cardiac, Gastrointestinal, Anti-diabetic medications
Branded Generics Market Dynamics
Corona Remedies operates in the branded generics segment, which dominates India's pharmaceutical market:
- Market Share: Branded generics represent >70% of Indian pharma market
- Growth Rate: 10.3% CAGR (2020-2027 projected)
- Key Advantage: Brand loyalty and premium pricing vs. unbranded generics
- Challenge: Government push towards generic prescriptions reducing margins
Competitive Landscape:Corona Remedies competes with larger, well-established companies like Abbott India, Alkem Labs, and Mankind Pharma. However, its focus on niche therapeutic areas (women's health, cardio-diabeto) provides competitive advantages and pricing power.
Corona Remedies IPO: Promoters & Leadership
Promoter Details:
Institutional Investors (Selling via OFS):
- ChrysCapital: 27.5% stake (will partially exit via IPO)
- Sepia Investments
- Anchor Partners
- Sage Investment Trust
Lock-in Period:
- 50% of anchor shares: 30-day lock-in (January 10, 2026)
- Remaining 50%: 90-day lock-in (March 11, 2026)
Product Portfolio Strengths
- Diversified Brands: 71 brands providing revenue stability
- Therapeutic Diversity: Presence across women's health, cardio, pain, urology
- Top Brand Performance: Top 10 brands contribute 47% of sales (growing)
- Combination Products: Innovative multi-drug formulations with competitive advantage
- Market-Specific Solutions: Products tailored to Indian market needs
Financial Capabilities
- Strong cash generation (₹245.91 crores EBITDA in FY25)
- Minimal debt burden (D/E ratio 0.10)
- Self-funding capacity for expansion
- No heavy capex requirements post-IPO
Corona Remedies IPO: Frequently Asked Questions (FAQs)
Q1: What is Corona Remedies IPO?
A: Corona Remedies IPO is a ₹655.37 crore Offer for Sale (OFS) by a leading Indian branded pharmaceutical company. It's listing on BSE and NSE on December 15, 2025, with price band ₹1,008-₹1,062 per share.
Q2: Is Corona Remedies IPO worth investing in?
A: Corona Remedies has strong fundamentals with 16.77% revenue CAGR, 41.32% ROCE, and excellent management. Suitable for 2-5 year investors seeking pharma sector exposure. However, aggressive valuation (P/E 43.47x) limits short-term gains.
Q3: What is the minimum investment for Corona Remedies IPO?
A: Minimum investment is ₹14,868 for retail investors (1 lot of 14 shares) at the upper price band of ₹1,062.
Q4: When is the Corona Remedies IPO opening and closing?
A: IPO opens on December 8, 2025, and closes on December 10, 2025. Bidding cut-off time is December 10 at 5 PM.
Q5: What is the expected listing date and price?
A: Expected listing date is December 15, 2025. Based on GMP of ₹290-₹300, expected listing price could be around ₹1,300-₹1,360. However, actual listing price depends on market conditions.
Q6: How do I apply for Corona Remedies IPO?
A: You can apply through:
- Online via IPO Ji (recommended) using UPI or net banking
- Online ASBA through your bank's website
- Offline ASBA at bank branch
- Through your stock broker
Q7: Is Corona Remedies an Offer for Sale (OFS) or Fresh Issue?
A: Corona Remedies IPO is entirely an Offer for Sale (OFS). There's no fresh issue component, meaning the company doesn't receive any IPO proceeds. All ₹655.37 crores go to selling shareholders.
Q8: What are the major risks in Corona Remedies IPO?
A: Key risks include aggressive valuation, intense market competition, regulatory pressure on drug pricing, and customer/distribution concentration. Company doesn't directly benefit from IPO proceeds.
Q9: Which therapeutic segments contribute most to Corona Remedies revenue?
A: Women's healthcare (28.56%) and Cardio-Diabeto (23.38%) are the largest contributors, accounting for over 50% of sales. These are high-margin chronic disease segments.
Q10: How does Corona Remedies compare to peers like Abbott and Alkem?
A: Corona Remedies has higher growth rate (16.77% vs. peers' 5-10%) and excellent returns (ROCE 41.32%), but lower scale. Valuation is moderate compared to Abbott (54x P/E) but higher than Alkem (33x P/E)
Disclaimer: This analysis is for informational purposes only and not investment advice. Always conduct your own due diligence and consult with a financial advisor before investing. Stock market investments carry risk, including potential loss of principal. Past performance doesn't guarantee future results.
